As per 30 September 2021, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi™) amounts to 307,114,495 shares. All shares are common shares. The total number of votes is 307,114,495. The increase in the number of shares and votes results from an issue of 3,298,984 class C shares. The class C shares have been issued for the purpose of ensuring fulfilment of commitments under incentive programmes and have by virtue of the conversion clause in the articles of association been converted to common shares. As per 30 September 2021 the company holds 11,969,866 common shares.
---
About Sobi™
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Sobi employs approximately 1,500 people across Europe, North America, the Middle East, Russia and Asia. In 2020, Sobi’s revenues amounted to SEK 15.3 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.
The above information has been made public in accordance with the Swedish Financial Instruments Trading Act. The information was released for public distribution on 30 September 2021 at 08:00 CEST.
For more information please contact
Thomas Kudsk Larsen, Head of Corporate Communication & Investor Relations
+44 7443 191 773
[email protected]
Paula Treutiger, Global Head of Communication
+46 733 666 599
[email protected]
This disclosure contains information that Swedish Orphan Biovitrum AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact person, on 30-09-2021 08:00 CET.
Swedish Orphan Biovitrum AB (publ)
Postal address SE-112 76 Stockholm, Sweden
Phone: 46 8 697 20 00 www.sobi.com
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Find out more about our business and financial performance.
Here we present our most recent press releases, news articles, and images.
Every day, we work actively to find better ways to understand and meet patient needs.